Prostamax
A peptide bioregulator designed to target prostate tissue, part of the five synthesized peptides developed by Khavinson demonstrating effects on gene expression and tissue-specific regulation.
Regulatory Pathway
Dosing Protocol
Typical Dose
10-20 mg daily
Frequency
Once or twice daily
Duration
10-30 day cycles
Timing & Administration
Administer via Oral capsules or sublingual. Frequency: Once or twice daily.
Popular Uses
Mechanism of Action
Regulates gene expression in prostate tissue through direct interaction with cellular DNA, modulating chromatin structure and transcription patterns specific to prostate cells.
Research Summary
Evidence level: animal studies. Clinical status: Preclinical research, approved in Russia as supplement.
Side Effects & Safety
Important Warnings
- Limited human data
- Not FDA approved.
References
No references available.
Related Peptides
Browse all →A tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Khavinson that modulates chromatin structure. Studies in elderly subjects (75-88 years) showed activation of ribosomal genes.
View profileA tripeptide bioregulator targeting liver and gastrointestinal tissue, derived from liver tissue extracts. Modulates gene expression related to detoxification, antioxidant defense, and cellular repair.
View profileA tetrapeptide bioregulator (Ala-Glu-Asp-Pro) derived from cerebral cortex extracts. Studied for neuroprotection, neural differentiation, and cognitive support.
View profile